Universidad de Guanajuato   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Guanajuato Mexico (1732)

Organization Overview

First Clinical Trial
2010
NCT02226263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Unidad de Investigación Metabólica, Universidad de Guanajuato, Boulevard Cañaveral 1001, fracciones de los Aguirre, CP 37672, León, Guanajuato, México | Universidad de Guanajuato

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 4)

Enterocolitis (Phase 2)

Enterocolitis, Necrotizing (Phase 2)

Glucose Intolerance (Phase 4)

Infections (Phase 3)

Insulin Resistance (Phase 4)

Malnutrition (Phase 2)

Neutropenia (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Prediabetic State (Phase 4)

Premature Birth (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 28